PHIO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 15:05):

Stats
Today's Volume	106 310
Average Volume	445 406
Market Cap	3.09M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.130
ATR14	$0.0100 (1.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Kontulis Caitlin	Sell	335	Common stock, $0.0001 par value
2024-02-26	Bitterman Robert J	Buy	2 500	Common stock, $0.0001 par value
2024-02-20	Bitterman Robert J	Sell	1 804	Common stock, $0.0001 par value
2024-02-15	Kontulis Caitlin	Sell	658	Common stock, $0.0001 par value
2024-02-17	Kontulis Caitlin	Sell	523	Common stock, $0.0001 par value

INSIDER POWER
77.38
Last 97 transactions
Buy: 3 139 429 \| Sell: 140 691

Volume Correlation

Long: -0.05 (neutral)

Short: 0.85 (strong)

Signal:(49.356) Same movement expected

Phio Pharmaceuticals Corp Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Phio Pharmaceuticals Corp Correlation - Currency/Commodity

0.21
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.41
( neutral )

-0.36
( neutral )

Phio Pharmaceuticals Corp Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-184 000 (0.00 %)
EPS:	$-5.20

Q4	2023
Revenue:	$0
Gross Profit:	$-43 000.00 (0.00 %)
EPS:	$-0.510

Q3	2023
Revenue:	$0
Gross Profit:	$-47 000.00 (0.00 %)
EPS:	$-1.140

Q2	2023
Revenue:	$0
Gross Profit:	$-47 000.00 (0.00 %)
EPS:	$-1.470

Financial Reports:

No articles found.

Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.